CA2625781C - Methods for the development of a biomolecule assay - Google Patents
Methods for the development of a biomolecule assay Download PDFInfo
- Publication number
- CA2625781C CA2625781C CA2625781A CA2625781A CA2625781C CA 2625781 C CA2625781 C CA 2625781C CA 2625781 A CA2625781 A CA 2625781A CA 2625781 A CA2625781 A CA 2625781A CA 2625781 C CA2625781 C CA 2625781C
- Authority
- CA
- Canada
- Prior art keywords
- protein
- ion
- fragments
- parent
- predicted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 93
- 238000003556 assay Methods 0.000 title claims abstract description 60
- 238000011161 development Methods 0.000 title abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 287
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 282
- 239000012634 fragment Substances 0.000 claims abstract description 204
- 230000002797 proteolythic effect Effects 0.000 claims abstract description 133
- 230000007704 transition Effects 0.000 claims abstract description 103
- 239000012530 fluid Substances 0.000 claims abstract description 20
- 238000002552 multiple reaction monitoring Methods 0.000 claims description 201
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 168
- 239000000523 sample Substances 0.000 claims description 123
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 94
- 210000002381 plasma Anatomy 0.000 claims description 72
- 238000001360 collision-induced dissociation Methods 0.000 claims description 56
- 210000004369 blood Anatomy 0.000 claims description 35
- 239000008280 blood Substances 0.000 claims description 35
- 238000002540 product ion scan Methods 0.000 claims description 32
- 238000005040 ion trap Methods 0.000 claims description 18
- 239000012472 biological sample Substances 0.000 claims description 15
- 238000011068 loading method Methods 0.000 claims description 15
- 238000013467 fragmentation Methods 0.000 claims description 14
- 238000006062 fragmentation reaction Methods 0.000 claims description 14
- 239000003480 eluent Substances 0.000 claims description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 9
- 238000012163 sequencing technique Methods 0.000 claims description 8
- 238000013519 translation Methods 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 5
- 206010036790 Productive cough Diseases 0.000 claims description 4
- 210000003567 ascitic fluid Anatomy 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 210000003756 cervix mucus Anatomy 0.000 claims description 4
- 210000000416 exudates and transudate Anatomy 0.000 claims description 4
- 210000002751 lymph Anatomy 0.000 claims description 4
- 238000007670 refining Methods 0.000 claims description 4
- 210000003296 saliva Anatomy 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 210000003802 sputum Anatomy 0.000 claims description 4
- 208000024794 sputum Diseases 0.000 claims description 4
- 210000004243 sweat Anatomy 0.000 claims description 4
- 210000001138 tear Anatomy 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 239000006166 lysate Substances 0.000 claims description 3
- 239000013592 cell lysate Substances 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 abstract description 10
- 150000002500 ions Chemical class 0.000 description 227
- 235000018102 proteins Nutrition 0.000 description 193
- 238000002474 experimental method Methods 0.000 description 48
- 238000004885 tandem mass spectrometry Methods 0.000 description 40
- 230000000875 corresponding effect Effects 0.000 description 20
- 238000001514 detection method Methods 0.000 description 19
- 238000013459 approach Methods 0.000 description 17
- 102100037362 Fibronectin Human genes 0.000 description 14
- 108010067306 Fibronectins Proteins 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 11
- 239000000090 biomarker Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 11
- 108010092694 L-Selectin Proteins 0.000 description 10
- 102000016551 L-selectin Human genes 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 230000029087 digestion Effects 0.000 description 9
- 238000010828 elution Methods 0.000 description 9
- 238000004949 mass spectrometry Methods 0.000 description 9
- 238000000126 in silico method Methods 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 6
- 108010071619 Apolipoproteins Proteins 0.000 description 6
- 102000007592 Apolipoproteins Human genes 0.000 description 6
- 102000004506 Blood Proteins Human genes 0.000 description 6
- 108010017384 Blood Proteins Proteins 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 208000001970 congenital sucrase-isomaltase deficiency Diseases 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 238000000132 electrospray ionisation Methods 0.000 description 6
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000002753 trypsin inhibitor Substances 0.000 description 6
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 102000014702 Haptoglobin Human genes 0.000 description 5
- 108050005077 Haptoglobin Proteins 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 238000010200 validation analysis Methods 0.000 description 5
- JCLFHZLOKITRCE-UHFFFAOYSA-N 4-pentoxyphenol Chemical compound CCCCCOC1=CC=C(O)C=C1 JCLFHZLOKITRCE-UHFFFAOYSA-N 0.000 description 4
- 101710095339 Apolipoprotein E Proteins 0.000 description 4
- 102100029470 Apolipoprotein E Human genes 0.000 description 4
- 108010028778 Complement C4 Proteins 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 102000004338 Transferrin Human genes 0.000 description 4
- 108090000901 Transferrin Proteins 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 239000012581 transferrin Substances 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 101710081722 Antitrypsin Proteins 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 102000013271 Hemopexin Human genes 0.000 description 3
- 108010026027 Hemopexin Proteins 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 108010026552 Proteome Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 101710193900 Vitamin K-dependent protein C Proteins 0.000 description 3
- 102100029477 Vitamin K-dependent protein C Human genes 0.000 description 3
- 230000001475 anti-trypsic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002731 protein assay Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 102000004411 Antithrombin III Human genes 0.000 description 2
- 108090000935 Antithrombin III Proteins 0.000 description 2
- 108010024284 Apolipoprotein C-II Proteins 0.000 description 2
- 102100039998 Apolipoprotein C-II Human genes 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108010014172 Factor V Proteins 0.000 description 2
- 101800001691 Inter-alpha-trypsin inhibitor light chain Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100032859 Protein AMBP Human genes 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 2
- 230000002788 anti-peptide Effects 0.000 description 2
- 229960005348 antithrombin iii Drugs 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- -1 for example Proteins 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 101150026046 iga gene Proteins 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 238000010844 nanoflow liquid chromatography Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- 102100036774 Afamin Human genes 0.000 description 1
- 101710149366 Afamin Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000003780 Clusterin Human genes 0.000 description 1
- 108090000197 Clusterin Proteins 0.000 description 1
- 102100037529 Coagulation factor V Human genes 0.000 description 1
- 101800000191 Coagulation factor XIIa light chain Proteins 0.000 description 1
- 102400000523 Coagulation factor XIIa light chain Human genes 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 102000006912 Complement C4b-Binding Protein Human genes 0.000 description 1
- 108010047548 Complement C4b-Binding Protein Proteins 0.000 description 1
- 108010027644 Complement C9 Proteins 0.000 description 1
- 102000016550 Complement Factor H Human genes 0.000 description 1
- 108010053085 Complement Factor H Proteins 0.000 description 1
- 102100031037 Complement component C9 Human genes 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100024783 Fibrinogen gamma chain Human genes 0.000 description 1
- 108090001064 Gelsolin Proteins 0.000 description 1
- 102000004878 Gelsolin Human genes 0.000 description 1
- 102100030386 Granzyme A Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108090000481 Heparin Cofactor II Proteins 0.000 description 1
- 102100030500 Heparin cofactor 2 Human genes 0.000 description 1
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 description 1
- 108010077861 Kininogens Proteins 0.000 description 1
- 102000010631 Kininogens Human genes 0.000 description 1
- 102100026636 MICOS complex subunit MIC26 Human genes 0.000 description 1
- 101710125126 MICOS complex subunit MIC26 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100038246 Retinol-binding protein 4 Human genes 0.000 description 1
- 101710137011 Retinol-binding protein 4 Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 101710097834 Thiol protease Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 108010048325 fibrinopeptides gamma Proteins 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002546 full scan Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical group [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003318 immunodepletion Methods 0.000 description 1
- 108010093564 inter-alpha-inhibitor Proteins 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000000534 ion trap mass spectrometry Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000005405 multipole Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012883 sequential measurement Methods 0.000 description 1
- 108010079003 sodium-influx-stimulating peptide Proteins 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012085 transcriptional profiling Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000011311 validation assay Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Electron Tubes For Measurement (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72718705P | 2005-10-13 | 2005-10-13 | |
| US60/727,187 | 2005-10-13 | ||
| PCT/US2006/040263 WO2007044935A2 (en) | 2005-10-13 | 2006-10-12 | Methods for the development of a biomolecule assay |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2625781A1 CA2625781A1 (en) | 2007-04-19 |
| CA2625781C true CA2625781C (en) | 2014-09-02 |
Family
ID=37847242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2625781A Expired - Fee Related CA2625781C (en) | 2005-10-13 | 2006-10-12 | Methods for the development of a biomolecule assay |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20070231909A1 (enExample) |
| EP (1) | EP1941280A2 (enExample) |
| JP (1) | JP5199101B2 (enExample) |
| CA (1) | CA2625781C (enExample) |
| WO (1) | WO2007044935A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7897405B2 (en) | 2008-02-11 | 2011-03-01 | Thermo Finnigan Llc | Method for identifying the elution time of an analyte |
| JP2009264949A (ja) * | 2008-04-25 | 2009-11-12 | Canon Anelva Technix Corp | イオン付着質量分析装置及びそのイオン付着質量分析方法 |
| WO2010056815A1 (en) * | 2008-11-12 | 2010-05-20 | The Washington University | Simultaneous measurment of the in vivo metabolism of isoforms of a biomolecule |
| EP2199956A1 (en) * | 2008-12-18 | 2010-06-23 | Siemens Aktiengesellschaft | Method and system for managing results of an analysis process on objects handled along a technical process line |
| UA112515C2 (uk) | 2009-06-03 | 2016-09-26 | Дау Аґросаєнсиз Елелсі | Спосіб виявлення присутності двох або більше білків, що становлять інтерес, в зразках рослинного походження |
| JP5408107B2 (ja) * | 2010-11-10 | 2014-02-05 | 株式会社島津製作所 | Ｍｓ／ｍｓ型質量分析装置及び同装置用プログラム |
| EP2715770B1 (en) * | 2011-06-03 | 2021-11-24 | DH Technologies Development Pte. Ltd. | Use of variable xic widths of tof-msms data for the determination of background interference in srm assays |
| JP6046144B2 (ja) * | 2011-09-22 | 2016-12-14 | エクスプレッション、パソロジー、インコーポレイテッドＥｘｐｒｅｓｓｉｏｎ Ｐａｔｈｏｌｏｇｙ， Ｉｎｃ． | 脂肪酸シンターゼタンパク質に対するｓｒｍ／ｍｒｍアッセイ |
| KR101431062B1 (ko) * | 2012-03-08 | 2014-08-21 | (주)바이오메디앙 | 유방암 진단용 다중 바이오마커 세트, 이의 검출 방법 및 이에 대한 항체를 포함하는 유방암 진단키트 |
| US9933416B1 (en) | 2013-07-30 | 2018-04-03 | Pioneer Hi-Bred International, Inc. | Detection and quantification of polypeptides in plants without a reference standard by mass spectrometry |
| JP6176049B2 (ja) * | 2013-10-11 | 2017-08-09 | 株式会社島津製作所 | タンデム四重極型質量分析装置 |
| CA2932378A1 (en) * | 2013-12-24 | 2015-07-02 | Dh Technologies Development Pte. Ltd. | High speed polarity switch time-of-flight spectrometer |
| US9720001B2 (en) * | 2014-05-21 | 2017-08-01 | Thermo Finnigan Llc | Methods for mass spectrometric biopolymer analysis using optimized weighted oligomer scheduling |
| BR112017006419A2 (pt) | 2014-09-30 | 2017-12-19 | Univ Washington | medições cinéticas de tau |
| US20180108521A1 (en) * | 2015-03-11 | 2018-04-19 | DH Technologies Development Pte Ltd. | Method of Increasing Quality of Tandem Mass Spectra |
| EP3334508B1 (en) | 2015-08-13 | 2024-12-18 | Waters Technologies Corporation | Alloy material devices and components |
| US10665442B2 (en) * | 2016-02-29 | 2020-05-26 | Shimadzu Corporation | Mass spectrometer |
| EP3491374B1 (en) | 2016-07-28 | 2024-10-09 | Waters Technologies Corporation | Encapsulated pre-analytic workflow reagents for flow-through devices, liquid chromatography and mass spectrometric analysis |
| US20220099637A1 (en) * | 2018-12-04 | 2022-03-31 | Bristol-Myers Squibb Company | Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring |
| US12105093B2 (en) | 2020-07-28 | 2024-10-01 | University Of Washington | Quantitation of GLA proteins by mass spectrometric analysis |
| CN112786105B (zh) * | 2020-12-07 | 2024-05-07 | 中山大学附属第五医院 | 一种宏蛋白质组挖掘方法及其在获取肠道微生物蛋白水解特征中的应用 |
| CN114487207A (zh) * | 2022-02-17 | 2022-05-13 | 杭州市食品药品检验研究院(杭州市食品药品审核查验服务中心、杭州市药品与医疗器械不良反应监测中心) | 一种同时鉴别10种龟鳖甲类中药的液质联用法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4121121A (en) * | 1977-09-13 | 1978-10-17 | Computer Identics Corporation | Follower response control circuit |
| US4361812A (en) * | 1978-12-04 | 1982-11-30 | Radiation Dynamics, Inc. | Voltage stabilized particle accelerator system and method |
| US5209919A (en) * | 1990-07-13 | 1993-05-11 | Regents Of The University Of California | Method of measurement in biological systems |
| US5668708A (en) * | 1996-03-13 | 1997-09-16 | Spellman High Voltage Electronics Corp. | DC power supply with reduced ripple |
| DE69622596T2 (de) * | 1996-10-25 | 2002-11-07 | Merska B.V., Groningen | Nicht-radioaktives rezeptorassay zur quantitativen und qualitativen analyse von spurenmengen eines rezeptorbindierendenanalytes |
| US6428956B1 (en) * | 1998-03-02 | 2002-08-06 | Isis Pharmaceuticals, Inc. | Mass spectrometric methods for biomolecular screening |
| AU765750B2 (en) * | 1998-06-04 | 2003-09-25 | Reprogen, Inc. | Use of cathepsin s in the diagnosis and treatment of endometriosis |
| ATE253126T1 (de) * | 1998-08-25 | 2003-11-15 | Univ Washington | Schnelle quantitative analyse von proteinen oder proteinfunktionen in komplexen gemischen |
| JP2002523114A (ja) * | 1998-08-31 | 2002-07-30 | ユニバーシテイ オブ ワシントン | バイオポリマーの分析のための安定なアイソトープ代謝性ラベリング |
| US6969614B1 (en) * | 1999-02-16 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for the isolation and analysis of cellular protein content |
| WO2000052035A1 (en) * | 1999-03-03 | 2000-09-08 | Princeton University | Bacterial transglycosylases: assays for monitoring the activity using lipid ii substrate analogs and methods for discovering new antibiotics |
| US6629040B1 (en) * | 1999-03-19 | 2003-09-30 | University Of Washington | Isotope distribution encoded tags for protein identification |
| US6391649B1 (en) * | 1999-05-04 | 2002-05-21 | The Rockefeller University | Method for the comparative quantitative analysis of proteins and other biological material by isotopic labeling and mass spectroscopy |
| US6936424B1 (en) * | 1999-11-16 | 2005-08-30 | Matritech, Inc. | Materials and methods for detection and treatment of breast cancer |
| US6770486B1 (en) * | 2000-02-08 | 2004-08-03 | Isis Pharmaceuticals, Inc. | Optimization of ligand affinity for RNA targets using mass spectrometry |
| US6858839B1 (en) * | 2000-02-08 | 2005-02-22 | Agilent Technologies, Inc. | Ion optics for mass spectrometers |
| IL152620A (en) * | 2000-05-05 | 2010-05-17 | Purdue Research Foundation | Affinity selected signature peptides for protein identification and quantification |
| EP1290450A2 (en) * | 2000-06-09 | 2003-03-12 | MDS Proteomics, Inc. | Labeling of proteomic samples during proteolysis for quantitation and sample multiplexing |
| CA2419159A1 (en) * | 2000-08-11 | 2002-02-21 | Agilix Corporation | Ultra-sensitive detection systems |
| US7045296B2 (en) * | 2001-05-08 | 2006-05-16 | Applera Corporation | Process for analyzing protein samples |
| DE10158860B4 (de) * | 2001-11-30 | 2007-04-05 | Bruker Daltonik Gmbh | Massenspektrometrische Proteingemischanalyse |
| GB0305796D0 (en) * | 2002-07-24 | 2003-04-16 | Micromass Ltd | Method of mass spectrometry and a mass spectrometer |
| GB0502068D0 (en) * | 2005-02-01 | 2005-03-09 | King S College London | Screening method |
-
2006
- 2006-10-12 WO PCT/US2006/040263 patent/WO2007044935A2/en not_active Ceased
- 2006-10-12 US US11/580,221 patent/US20070231909A1/en not_active Abandoned
- 2006-10-12 CA CA2625781A patent/CA2625781C/en not_active Expired - Fee Related
- 2006-10-12 EP EP06816949A patent/EP1941280A2/en not_active Ceased
- 2006-10-12 JP JP2008535752A patent/JP5199101B2/ja not_active Expired - Fee Related
-
2009
- 2009-10-01 US US12/572,042 patent/US8187893B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2625781A1 (en) | 2007-04-19 |
| WO2007044935A3 (en) | 2007-10-18 |
| WO2007044935A2 (en) | 2007-04-19 |
| EP1941280A2 (en) | 2008-07-09 |
| JP2009511915A (ja) | 2009-03-19 |
| JP5199101B2 (ja) | 2013-05-15 |
| US8187893B2 (en) | 2012-05-29 |
| US20070231909A1 (en) | 2007-10-04 |
| US20100233815A1 (en) | 2010-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8187893B2 (en) | Mass spectrometric based assay for presence of a protein without the use of a standard | |
| Gallien et al. | Selected reaction monitoring applied to proteomics | |
| US8809062B2 (en) | Method and apparatus for fractionation-based chemical analyses | |
| US9146213B2 (en) | Method and apparatus for performing retention time matching | |
| US8592752B2 (en) | Techniques for performing retention-time matching of precursor and product ions and for constructing precursor and product ion spectra | |
| US8373115B2 (en) | Method and apparatus for identifying proteins in mixtures | |
| US8221967B2 (en) | Method for quantification of peptide and protein | |
| EP2035829A2 (en) | Mass spectrometry biomarker assay | |
| EP4033250A1 (en) | Method of assaying the purity of a therapeutic polypeptide | |
| US20080206737A1 (en) | Expression quantification using mass spectrometry | |
| WO2024261668A1 (en) | Apparatus and methods to correlate spike protein urinary metabolism with body health | |
| HK40077213A (en) | Method of assaying the purity of a therapeutic polypeptide | |
| Eng et al. | Computational tools for tandem mass spectrometry-based high-throughput quantitative proteomics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20201013 |